ABL Bio

298380.KQ

119.47 USD

-0.03

-0.03%

Overview

Last close

119.47 usd

Market cap

6.59B usd

52 week high

171.55 usd

52 week low

18.25 usd

Target price

138.71 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

125.1173

Price/Book Value

67.8735

Enterprise Value

6.92B usd

EV/Revenue

131.591

EV/EBITDA

-32.1061

Key financials

Revenue TTM

52.61M usd

Gross Profit TTM

52.53M usd

EBITDA TTM

-24.49M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

194.73M usd

Net debt

N/A usd

About

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.